2026-04-13T02:06:26Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4583272026-03-13T07:54:09Zcom_2072_98col_2072_378192

urn:hdl:2072/458327 Wharton's jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit : an experienced view Muñoz-Domínguez, Noelia Roura, Santiago Prat-Vidal, Cristina Vives Armengol, Joaquim Universitat Autònoma de Barcelona Biomanufacturing Cardiac tissue engineering Clinical translation Extracellular vesicles Mesenchymal stromal cells Myocardial infarction Wharton's jelly Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particu-larly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton's jelly MSC and derived EV in post-MI management. 2021 Article Instituto de Salud Carlos III PI18/00256 Instituto de Salud Carlos III PI18/01227 Instituto de Salud Carlos III PI19/01788 Instituto de Salud Carlos III PI17/01487 Instituto de Salud Carlos III PIC18/00014 Instituto de Salud Carlos III ICI19/00039 Instituto de Salud Carlos III ICI20/00135 Agencia Estatal de Investigación PID2019-110137RB-I00 Agencia Estatal de Investigación SAF2017-84324-C2-1-R Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-483 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-719 Agència de Gestió d'Ajuts Universitaris i de Recerca 2019PROD00122 Pharmaceutics ; Vol. 13 Núm. 9 (september 2021), p. 1336 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/